Erratum to: Zidovudine: An Update of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy

Abstract

1080 Stiderberg M, Lundgren R, Angstrom T. Effect of cetirizine on histamine-induced bronchoconstriction and bronchoalveolar cells. Allergy 46: 217-221,1991 Spyropoulou-Vlahou M, Stavropoulos-Giokas A, Filippou M, Koyas A, Kontou-Fili K. Clinical and laboratory results confirm the efficacy of cetirizine 2HCI in seasonal allergic rhinitis. Acta Therapeutica 16: 71-78, 1990 Tashkin DP, Brik A, Gong Jr H. Cetirizine inhibition of histamineinduced bronchospasm. Annals of Allergy 59 (Part II): 49-52, 1987 Tjwa MKT, Widjaja P, DelBono L, Pichler WJ, Backhouse CI, et al. Loratadine compared to cetirizine in patients with seasonal allergic rhinitis. Abstract. Allergy 47 (Suppl.): 174, 1992 van Neste D, Coussement C, Ghys L, Rihoux J-P. Agonist-antagonist interactions in the skin: comparison of effects of loratadine and cetirizine on skin vascular responses to prick tests with histamine and substances P. Journal of Dermatological Science 4: 172-179, 1992 Varney V, Gaga M, Frew AJ, De Vos C, Kay AB. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects.

A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity

“…Women with hyperlipidaemia have been shown to be prescribed antihyperlipidaemic drugs less often in clinical practice than men; thus, any treatment option that avoids exacerbating lipid abnormalities in women would be desirable. The HDL-cholesterol results of this study are generally consistent with previous research with the study drugs [15][16][17]. None of the regimens resulted in a significant change in HDL cholesterol, although week-96 results showed that the largest LSM increase from baseline was observed in women treated with TZV ( 1 8 mg/dL).…”

Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase

“…Of the licensed HIV-1 RT inhibitors, AZT has been in clinical use for the longest time (for a review see Wilde & Langtry, 1993). Consequently, many combination therapy trials have been designed where additional antiretroviral drugs are used with AZT.…”

Antiviral β-L-nucleosides specific for hepatitis B virus infection

“…Since long-term treatment is expected for chronic HBV infection, drug selectivity is a critical issue. Toxic side effects have been a major problem, limiting the clinical use of some nucleoside analogs (17,25,53,54). The 5Ј-triphosphates of L-dC, L-dT, and L-dA did not inhibit human DNA polymerases ␣, ␤, and ␥ at concentrations up to 100 M. Semizarov and coworkers also reported that the 5Ј-triphosphates of L-dC and L-dT were not substrates for human DNA polymerases (42).…”

“…, and zalcitabine (␤-D-2Ј,3Ј-dideoxycytidine [ddC]), have shown clinically limiting delayed toxicities such as peripheral neuropathy, myopathy, and pancreatitis (17,25,53,54). This nucleoside analogrelated cellular toxicity has been attributed to decreased mtDNA content and altered mitochondrial function, leading to increased lactic acid production (5, 9-12, 28, 35).…”